ArticleBMC complementary medicine and therapies2025
A novel comprehensive strategy for research on wine-processed mechanism of corni fructus guided by variation in the chemical components and network analysis.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCorni Fructus, a plant with both medicinal and edible properties, is renowned for its aromatic flavor and hepatoprotective and renoprotective effects, offering significant nutritional value and broad application potential. Wine-processed Corni Fructus (WCF) is a primary processed form of Corni Fructus, widely utilized in food supplements. Traditional Chinese medicine suggests that wine-processing enhances its hepatoprotective and renoprotective properties, yet the underlying mechanisms remain unclear.
objectiveIn this study, a novel comprehensive strategy guided by variation in the chemical components and differences in biological activities was developed to explore the wine-processing mechanisms. MATERIALS AND
methodsFirstly, the chemical constituents in vitro and in vivo were identified by liquid chromatography coupled to high-resolution mass spectrometry liquid chromatography-mass spectrometry (LC-MS). Furthermore, chemometric analysis was applied to investigate the chemical characteristics in the samples with different processing methods. The possible molecular mechanism differences were unraveled by network pharmacology.
resultsA total of 53 and 61 components were identified in vitro of crude Corni Fructus (CCF) and WCF, respectively. In addition, 39 and 43 components were detected in rats' serum after CCF and WCF administered by gavage. Ten common targets were identified as key targets for the therapeutic effects of CCF and WCF on Chronic kidney diseases (CKD). The network analysis showed that 23 components in WCF may be the active substances that make it more effective than CCF for treating CKD.
conclusionsThis study provides a theoretical basis for the pharmacological substances of WCF and CCF and gives insights into comparing their pharmacological differences. It further investigates the mechanisms underlying different processing techniques of Corni Fructus, supporting further exploration of its potential in CKD management. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.